NEWTOWN, Pa., Feb. 9 /PRNewswire/ -- CollaGenex Pharmaceuticals, Inc.
(Nasdaq: CGPI), today announced that it will hold a conference call on
Tuesday, February 13, 2001, at 11:00 a.m. (ET) to discuss fourth-quarter and
year-end results. The call can be accessed via the Internet through
http://www.vcall.com . The conference call will be available for replay on Vcall's
website for a period of 90 days.
About the Company
CollaGenex Pharmaceuticals, Inc. is a specialty pharmaceutical company
focused on providing innovative medical therapies to the dental market.
The company's lead product, Periostat(R), was approved by the FDA in September
1998 and is the first and only pharmaceutical to treat periodontal disease
by inhibiting the enzymes that destroy periodontal support tissues. Periostat
is marketed to the dental community by CollaGenex through a professional
pharmaceutical sales force composed of approximately 120 sales representatives
and managers. Currently, the company's sales force is also marketing
VIOXX(R), a Merck & Co. drug that the company promotes for the treatment and
relief of acute dental pain, and Denavir(R), a Novartis Pharmaceuticals
Corporation product for the treatment of cold sores.
To receive additional information on the Company, please visit our Web
site at http://www.collagenex.com .
SOURCE CollaGenex Pharmaceuticals, Inc.
 back to top
Related links:
http://www.collagenex.com
CONTACT:
Nancy Broadbent, Chief Financial Officer of
CollaGenex Pharmaceuticals, Inc., 215-579-7388; or General, Kathy
Brunson, 312-640-6696, or kbrunson@bsmg.com, Analysts-Investors,
Leslie Loyet, 312-640-6672, or lloyet@bsmg.com, all of The
Financial Relations Board-BSMG Worldwide
|
